Corcept Therapeutics Incorporated CORT Stock
Corcept Therapeutics Incorporated Price Chart
Corcept Therapeutics Incorporated CORT Financial and Trading Overview
| Corcept Therapeutics Incorporated stock price | 77.23 USD |
| Previous Close | 22.72 USD |
| Open | 22.76 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 22.63 - 23.2 USD |
| 52 Week Range | 17.86 - 30.14 USD |
| Volume | 639.24K USD |
| Avg. Volume | 785.3K USD |
| Market Cap | 2.36B USD |
| Beta (5Y Monthly) | 0.494014 |
| PE Ratio (TTM) | 28.987501 |
| EPS (TTM) | 0.87 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.67 USD |
CORT Valuation Measures
| Enterprise Value | 1.89B USD |
| Trailing P/E | 28.987501 |
| Forward P/E | 38.649998 |
| PEG Ratio (5 yr expected) | -0.92 |
| Price/Sales (ttm) | 5.6922603 |
| Price/Book (mrq) | 4.73652 |
| Enterprise Value/Revenue | 4.57 |
| Enterprise Value/EBITDA | 18.653 |
Trading Information
Corcept Therapeutics Incorporated Stock Price History
| Beta (5Y Monthly) | 0.494014 |
| 52-Week Change | 12.02% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 30.14 USD |
| 52 Week Low | 17.86 USD |
| 50-Day Moving Average | 23.23 USD |
| 200-Day Moving Average | 23.67 USD |
CORT Share Statistics
| Avg. Volume (3 month) | 785.3K USD |
| Avg. Daily Volume (10-Days) | 484.03K USD |
| Shares Outstanding | 101.58M |
| Float | 82.97M |
| Short Ratio | 24.26 |
| % Held by Insiders | 11.59% |
| % Held by Institutions | 83.62% |
| Shares Short | 16.73M |
| Short % of Float | 26.77% |
| Short % of Shares Outstanding | 16.46% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 22.83% |
| Operating Margin (ttm) | 24.33% |
| Gross Margin | 98.66% |
| EBITDA Margin | 24.49% |
Management Effectiveness
| Return on Assets (ttm) | 11.59% |
| Return on Equity (ttm) | 20.16% |
Income Statement
| Revenue (ttm) | 413.82M USD |
| Revenue Per Share (ttm) | 3.86 USD |
| Quarterly Revenue Growth (yoy) | 12.80% |
| Gross Profit (ttm) | 396.47M USD |
| EBITDA | 101.38M USD |
| Net Income Avi to Common (ttm) | 94.3M USD |
| Diluted EPS (ttm) | 0.8 |
| Quarterly Earnings Growth (yoy) | -30.30% |
Balance Sheet
| Total Cash (mrq) | 465.06M USD |
| Total Cash Per Share (mrq) | 4.58 USD |
| Total Debt (mrq) | 575K USD |
| Total Debt/Equity (mrq) | 0.11 USD |
| Current Ratio (mrq) | 6.77 |
| Book Value Per Share (mrq) | 4.896 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 111.03M USD |
| Levered Free Cash Flow (ttm) | 105.44M USD |
Profile of Corcept Therapeutics Incorporated
| Country | United States |
| State | CA |
| City | Menlo Park |
| Address | 149 Commonwealth Drive |
| ZIP | 94025 |
| Phone | 650 327 3270 |
| Website | https://www.corcept.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 299 |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Q&A For Corcept Therapeutics Incorporated Stock
What is a current CORT stock price?
Corcept Therapeutics Incorporated CORT stock price today per share is 77.23 USD.
How to purchase Corcept Therapeutics Incorporated stock?
You can buy CORT shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Corcept Therapeutics Incorporated?
The stock symbol or ticker of Corcept Therapeutics Incorporated is CORT.
Which industry does the Corcept Therapeutics Incorporated company belong to?
The Corcept Therapeutics Incorporated industry is Biotechnology.
How many shares does Corcept Therapeutics Incorporated have in circulation?
The max supply of Corcept Therapeutics Incorporated shares is 105.37M.
What is Corcept Therapeutics Incorporated Price to Earnings Ratio (PE Ratio)?
Corcept Therapeutics Incorporated PE Ratio is 88.77012000 now.
What was Corcept Therapeutics Incorporated earnings per share over the trailing 12 months (TTM)?
Corcept Therapeutics Incorporated EPS is 0.87 USD over the trailing 12 months.
Which sector does the Corcept Therapeutics Incorporated company belong to?
The Corcept Therapeutics Incorporated sector is Healthcare.
Corcept Therapeutics Incorporated CORT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 22867.65 USD — |
+2.67
|
5.4B USD — | 22478.27 USD — | 22879.73 USD — | — - | 5.4B USD — |
| US Tech Global BuyBack Achievers DRBG | 2620.72 USD — |
+0.57
|
— — | 2601.67 USD — | 2624.95 USD — | — - | — — |
| US Tech Capital Market Composite RCMP | 121.21 USD — |
+2.11
|
— — | 118.96 USD — | 121.29 USD — | — - | — — |
| US Tech US Smart Pharmaceuticals NQSSPH | 1722.61 USD — |
+1.06
|
— — | 1714.23 USD — | 1733.66 USD — | — - | — — |
| US Tech US BuyBack Achievers Sel DRBS | 2340.09 USD — |
+0.42
|
— — | 2336.31 USD — | 2349.71 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 28067.72 USD — |
+2.55
|
— — | 27623.43 USD — | 28116.78 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2521.76 USD — |
+1.4
|
— — | 2488.06 USD — | 2528.45 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 3344.89 USD — |
+2.06
|
— — | 3293.71 USD — | 3356.91 USD — | — - | — — |
| US Tech Health Care IXHC | 1184.66 USD — |
+1.31
|
— — | 1172.93 USD — | 1188.24 USD — | — - | — — |
- {{ link.label }} {{link}}